Key facts
- NovaGray’s last known valuation is $12.6M (Apr 2020).
- It has raised $33.2M; the latest was Later Stage VC ($31.2M) in Feb 2025.
- Notable investors include MedTech Innovator, Boost Invest MedVallée, Grégoire Briens, Horizon 2020, La Synapse — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for NovaGray
- ·The full record, as it builds
Funding rounds
No funding rounds for NovaGray are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NovaGray
Developer of companion diagnostic tests intended to improve radiation therapy planning. The company's biomarker-based tests assess patients' sensitivity for personalizing radiotherapy using a single blood sample, enabling physicians to personalize standard treatments to patients' sensitivity in order to improve outcomes and reduce complication costs as well as treatment costs.
- Sector
- Healthcare
- HQ
- Montpellier, France
- Founded
- 2015
- Employees
- 6
- Website
- nova-gray.com/
- Ownership
- Privately Held (backing)
NovaGray doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NovaGray shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NovaGray in its N-PORT filings yet. We sweep new filings monthly.